Key Takeaways
- Aflibercept 8 mg significantly reduced macular thickness, PED height, and retinal fluid at 1 year.
- Visual acuity gains were small and highly variable despite strong anatomical improvements.
- More than half of eyes were extended to ≥12-week dosing intervals using an anatomy-driven approach.
In a real-world cohort of treatment-naïve patients with neovascular age-related macular degeneration (nAMD), aflibercept 8 mg produced substantial anatomical improvements and allowed extended dosing intervals over 1 year.
The observational, retrospective case series included data from 9 centers and assessed visual and anatomical changes over 12 months.
The analysis included 91 eyes treated with intravitreal aflibercept 8 mg. After 1 year, mean visual acuity increased by 1.0 ± 13.2 letters (P = 0.018). Mean central subfield thickness decreased by 110.0 ± 130.9 µm (P < 0.001), and mean pigment epithelial detachment height was reduced by 71.2 ± 104.8 µm (P < 0.001). At 12 months, 66.2% of eyes showed complete absence of macular fluid.
The average treatment interval was 13.9 ± 7.9 weeks, and 56.1% of eyes were extended to intervals of ≥ 12 weeks using an anatomy-driven approach. No functional or anatomical differences were found between eyes that completed a clean loading phase or among different macular neovascularization subtypes. Two adverse events were reported during the study period.
Reference
Grimaldi G, Bartolomeo N, Garweg JG, et al. One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. Ophthalmol Ther. 2026;doi: 10.1007/s40123-025-01305-w. Epub ahead of print. PMID: 41634482.
Related Content
